Molecular Profiling Reveals Favorable Risk Pattern in Rare Aggressive Uterine Cancer
News, Oncoscience, Trending
August 4, 2026“Application of molecular classification in all cases of endometrial carcinoma is encouraged for prognostic risk-group stratification and as a potential influence on adjuvant or systemic treatment decisions.”
BUFFALO, NY — August 4, 2026 — A new case report was published in Volume 13 of Oncoscience on July 29, 2026, titled “Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report.”
The report was led by first author Aparna Jarathi from the Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences (AIIMS), Bibinagar, India. The corresponding author is Akhila Pagolu, from the same department. The authors describe a rare case of uterine carcinosarcoma with a dual molecular signature that may provide important insights into how molecular profiling can refine prognosis and help guide treatment decisions for patients with aggressive endometrial cancers.
Uterine carcinosarcoma, also known as malignant mixed Müllerian tumor, accounts for fewer than 5% of uterine cancers but is responsible for a disproportionately high number of deaths from uterine malignancies because of its aggressive behavior and high risk of recurrence. In recent years, molecular classification has become an important component of endometrial cancer evaluation, allowing clinicians to classify tumors according to specific genetic alterations that can influence prognosis and therapeutic strategies. Among these molecular subtypes, tumors carrying more than one molecular classifier are uncommon and remain relatively poorly understood.
The report describes a 64-year-old postmenopausal woman who presented with abnormal uterine bleeding and vaginal discharge. Imaging identified an endometrial mass, and biopsy revealed a biphasic tumor containing both malignant epithelial and sarcomatous components, consistent with uterine carcinosarcoma. The patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, pelvic lymph node dissection, omentectomy, peritoneal biopsy, and peritoneal fluid cytology. Pathological examination showed a high-grade endometrioid homologous uterine carcinosarcoma confined to the endometrium, without myometrial invasion, lymphovascular space invasion, lymph node involvement, or spread to surrounding organs.
To further characterize the tumor, the investigators performed next-generation sequencing. Molecular testing identified both a TP53 abnormality and an MSH6 mismatch repair deficiency (MMRd) frameshift mutation, classifying the tumor as the rare MMRd-p53abn dual-classifier subtype. Previous studies have suggested that tumors with this molecular profile tend to behave more like single-classifier MMR-deficient cancers than tumors driven primarily by p53 abnormalities, which are generally associated with a poorer prognosis. This molecular information therefore provided additional context for assessing the patient’s expected clinical course.
Following surgery, the patient received six cycles of adjuvant carboplatin and paclitaxel chemotherapy, the current preferred first-line regimen for uterine carcinosarcoma. During follow-up, she experienced one transient ischemic attack after completing chemotherapy but recovered without residual neurological deficits. She continued regular surveillance with scheduled imaging to monitor for recurrence.
The case also highlights the growing importance of integrating molecular classification into routine clinical practice. Current international guidelines increasingly recommend evaluating endometrial cancers for molecular alterations such as POLE mutations, mismatch repair deficiency, and p53 abnormalities, because these markers improve prognostic risk stratification and may influence decisions regarding adjuvant therapy. In particular, tumors with mismatch repair deficiency may also be candidates for immune checkpoint inhibitor therapy, reflecting the expanding role of precision medicine in gynecologic oncology.
“MMRd-p53abn may have a better survival rate when a multimodal, individualised, tailored approach is followed. Novel molecular-targeted therapies could potentially improve patient care and outcomes.”
Although this report describes only a single patient and cannot establish outcomes for all patients with this rare cancer subtype, it illustrates how combining imaging, pathology, surgery, and comprehensive molecular testing can improve clinical decision-making. The authors emphasize that molecular classification should become part of routine evaluation for endometrial carcinomas to better identify patients who may benefit from individualized treatment strategies and emerging targeted therapies.
Overall, this case demonstrates the clinical value of molecular profiling in one of the most aggressive forms of uterine cancer. By identifying a rare dual-classifier molecular signature associated with a potentially more favorable prognosis than expected, the report supports the growing role of precision oncology in improving risk assessment, guiding treatment selection, and advancing personalized care for patients with endometrial carcinoma.
DOI: https://doi.org/10.18632/oncoscience.665
Correspondence to: Akhila Pagolu – pagoluakhila1996@gmail.com
Keywords: chemotherapy, pole mutant, MMRd-P53 abn, postmenopausal, uterine carcinosarcoma
Click here to sign up for free Altmetric alerts about this article.
About Oncoscience:
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: freeing oncology from publication costs. It is free to readers and authors.
Oncoscience is indexed and archived by PubMed, PubMed Central, Scopus, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
For media inquiries, please contact media@impactjournals.com.
